Trial Profile
A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Oedema Secondary to Branch Retinal Vein Occlusion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Branch retinal vein occlusion; Retinal oedema
- Focus Registrational; Therapeutic Use
- Acronyms BRAVO
- Sponsors Genentech
- 15 Aug 2014 New trial record
- 04 Mar 2010
- 03 Feb 2009